Skip to main content
. Author manuscript; available in PMC: 2013 Nov 27.
Published in final edited form as: J Mol Cell Cardiol. 2010 Jan 29;48(6):10.1016/j.yjmcc.2010.01.014. doi: 10.1016/j.yjmcc.2010.01.014

Figure 4.

Figure 4

Percent recovery of post-ischemic cardiac function in Wt (black bar) and FGF2 HMWKO (dark gray bar) hearts following DMSO (vehicle) or PD173074 (25 nM) treatment. Inhibition of FGFR with PD173074 (25 nM) completely abolished the FGF2 HMWKO post-ischemic recovery of contractile function. Recovery of cardiac function was calculated as the percent +dP/dt at 120 minutes reperfusion to baseline measure. n=6 for vehicle (DMSO)- and PD173074-treated Wt and FGF2 HMWKO hearts. *p<0.05 vs. vehicle (DMSO)-treated cohort. #p<0.05 vs. vehicle (DMSO)-treated Wt hearts.